Edesa Biotech entered into an underwriting agreement with Guggenheim Securities for a registered public offering of common shares and accompanying warrants. The company sold 3,870,500 common shares at $5.50 per share and accompanying warrants to purchase up to 3,870,500 additional shares. Additionally, the company issued pre-funded warrants to purchase up to 675,000 common shares at a combined price of $5.4999 per warrant and accompanying warrant. The underwriters received a 30-day option to purchase up to 681,825 additional shares on identical terms. Gross proceeds are expected to be approximately $25.0 million, with net proceeds estimated at $23.1 million after deducting discounts and expenses. The offering closed on or about August 21, 2026. Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases.
